Q4 FY2023 Earnings August 3, 2023 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial ...

ResMed, Inc. (NYSE:RMD) Q4 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications & IRO Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President & COO Lucile Blaise - President, Sleep & Respiratory Care Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Margaret Kaczor - William Blair Anthony Petrone - Mizuho Group Shaymus Contorno - Oppenheimer Laura Sutcliffe - UBS Sean Laaman - Morgan Stanley Lyanne Harrison - Bank of Am ...

ResMed Inc. (NYSE:RMD) Q3 2023 Earnings Conference Call April 27, 2023 4:30 PM ET Company Participants Amy Wakeham - Vice President, Investor Relations Mick Farrell - Chief Executive Officer and Chairman Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer David Pendarvis - Global General Counsel, Chief Administrative Officer Conference Call Participants Lyanne Harrison - Bank of America Dan Hurren - MST Macquarie Gretel Janu - Credit Suisse Matt Taylor - Jefferies ...

Q3 FY2023 Earnings April 27, 2023 In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

ResMed Inc. (NYSE:RMD) Q2 2023 Earnings Conference Call January 26, 2023 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO and Chairman Brett Sandercock - CFO Rob Douglas - President and COO Conference Call Participants Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Steve Wheen - Jarden David Bailey - Macquarie Mike Matson - Needham & Company Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margaret Kaczor - W ...

Q2 FY2023 Earnings January 26, 2023 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...